Angela Colbers, José Moltó, Jelena Ivanovic, Kabamba Kabeya, David Hawkins, Andrea Gingelmaier, Graham Taylor, Katharina Weizsäcker, S Tariq Sadiq, Marchina Van der Ende, Carlo Giaquinto, David Burger
OBJECTIVES: To describe the pharmacokinetics of darunavir in pregnant HIV-infected women in the third trimester and post-partum. PATIENTS AND METHODS: This was a non-randomized, open-label, multicentre, Phase IV study in HIV-infected pregnant women recruited from HIV treatment centres in Europe. HIV-infected pregnant women treated with darunavir (800/100 mg once daily or 600/100 mg twice daily) as part of their combination ART were included. Pharmacokinetic curves were recorded in the third trimester and post-partum...
February 2015: Journal of Antimicrobial Chemotherapy